Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations

• KEARNS GL, ABDEL-RAHMAN SM, ALANDER SW, BLOWEY DL, LEEDER JS, KAUFFMAN RE: Developmental pharmacology–drug disposition, action, and therapy in infants and children. N. Engl. J. Med. (2003) 349(12):1157-1167.
   PubMed Web of Science ®Google Scholar
• ROSS JS, SCHENKEIN DP, KASHALA O et al.: Pharmacogenomics. Adv. Anat. Pathol. (2004) 11(4):211-220.
   PubMed Web of Science ®Google Scholar
• MEYER UA: Pharmacogenetics and adverse drug reactions. Lancet (2000) 356(9242):1667-1671.
   PubMed Web of Science ®Google Scholar
• HAAS CE, FORREST A: Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need. Crit. Care Med. (2006) 34(6):1831-1833.
   PubMed Web of Science ®Google Scholar
• YENDE S, KAMMERER CM, ANGUS DC: Genetics and proteomics: deciphering gene association studies in critical illness. Crit. Care (2006) 10(4):227.
   PubMedGoogle Scholar
• PARK F, GOW KW: Gene therapy: future or flop. Pediatr. Clin. North Am. (2006) 53(4):621-638.
   PubMed Web of Science ®Google Scholar
• BELFER I, WU T, KINGMAN A, KRISHNARAJU RK, GOLDMAN D, MAX MB: Candidate gene studies of human pain mechanisms: methods for optimizing choice of polymorphisms and sample size. Anesthesiology (2004) 100(6):1562-1572.
   PubMed Web of Science ®Google Scholar
• VAN DEN ANKER JN, VAN SCHAIK RH, TIBBOEL D: Pharmacogenetics and pharmacogenomics of morphine. In: Pain in Neonates. Anand KJS, Stevens R, McGarth P (Eds), Elsevier (2007).
   Google Scholar
• LOTSCH J, GEISSLINGER G: Current evidence for a genetic modulation of the response to analgesics. Pain (2006) 121(1-2):1-5.
   PubMed Web of Science ®Google Scholar
• MARSH S, MCLEOD HL: Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. (2006) 15(Spec. No. 1):R89-R93.
   PubMed Web of Science ®Google Scholar
• DANHOF M, DE JONGH J, DE LANGE EC, DELLA PASQUA O, PLOEGER BA, VOSKUYL RA: Mechanism-based pharmacokinetic–pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. (2006) 47:357-400.
   Web of Science ®Google Scholar
• BARTELINK IH, RADEMAKER CM, SCHOBBEN AF, VAN DEN ANKER JN: Guidelines on pediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. (2006) 45(11):1077-1097.
   PubMed Web of Science ®Google Scholar
• DE WILDT SN, KEARNS GL, LEEDER JS, VAN DEN ANKER JN: Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. (1999) 36(6):439-452.
   PubMed Web of Science ®Google Scholar
• MCINTYRE J, CHOONARA I: Drug toxicity in the neonate. Biol. Neonate (2004) 86(4):218-221.
   PubMedGoogle Scholar
• SUTHERLAND JM: Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J. Dis. Child (1959) 97(6):761-767.
   PubMedGoogle Scholar
• COULET A, SMAÍL-TABBONE M, NAPOLI A, DEVIGNES MD: Suggested Ontology for Pharmacogenomics (SO-Pharm): modular construction and preliminary testing. Proceedings of the International Workshop on Knowledge Systems in Bioinformatics. Montpellier, France (2006) KSinBIT'06.
   Google Scholar
• CHATZIDAKIS K, GOULAS A, ATHANASSIADOU-PIPEROPOULOU F, FIDANI L, KOLIOUSKAS D, MIRTSOU V: Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in greek patients. Pediatr. Blood Cancer (2006) 47(2):147-151.
   PubMed Web of Science ®Google Scholar
• ZIELINSKA E, NIEWIAROWSKI W, BODALSKI J: The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. Eur. J. Clin. Pharmacol. (1998) 54(9-10):779-785.
   PubMed Web of Science ®Google Scholar
• TISSING WJ, MEIJERINK JP, DEN BOER ML et al.: Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin. Cancer Res. (2005) 11(16):6050-6056.
   PubMed Web of Science ®Google Scholar
• MINAMI T, SUZUKI H, TAKEUCHI T, UEMURA S, SUGATANI J, YOSHIKAWA N: A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J. Pediatr. (2005) 147(1):78-83.
   PubMed Web of Science ®Google Scholar
• ANSARI M, KRAJINOVIC M: Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr. Opin. Pediatr. (2007) 19(1):15-22.
   PubMed Web of Science ®Google Scholar
• ORY HW: Association between oral contraceptives and myocardial infarction. A review. JAMA (1977) 237(24):2619-2622.
   PubMed Web of Science ®Google Scholar
• SCHWINGL PJ, ORY HW, VISNESS CM: Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States. Am. J. Obstet. Gynecol. (1999) 180(1 Part 1):241-249.
   PubMed Web of Science ®Google Scholar
• JAIN AK: Cigarette smoking, use of oral contraceptives, and myocardial infarction. Am. J. Obstet. Gynecol. (1976) 126(3):301-307.
   PubMed Web of Science ®Google Scholar
• GRIMES DA, SCHULZ KF: Bias and causal associations in observational research. Lancet (2002) 359(9302):248-252.
   PubMed Web of Science ®Google Scholar
• BOFFETTA P: Molecular epidemiology. J. Intern. Med. (2000) 248(6):447-454.
   PubMed Web of Science ®Google Scholar
• CARDON LR, PALMER LJ: Population stratification and spurious allelic association. Lancet (2003) 361(9357):598-604.
   PubMed Web of Science ®Google Scholar
• THOMAS DC, WITTE JS: Point: population stratification: a problem for case-control studies of candidate-gene associations? Cancer Epidemiol. Biomarkers Prev. (2002) 11(6):505-512.
   PubMed Web of Science ®Google Scholar
• STEPHENSON T: How children's responses to drugs differ from adults. Br. J. Clin. Pharmacol. (2005) 59(6):670-673.
   PubMed Web of Science ®Google Scholar
• MANJI N, CARR-SMITH JD, BOELAERT K et al.: Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J. Clin. Endocrinol. Metab. (2006) 91(12):4873-4880.
   PubMed Web of Science ®Google Scholar
• PARIENTE-KHAYAT A, REY E, GENDREL D et al.: Isoniazid acetylation metabolic ratio during maturation in children. Clin. Pharmacol. Ther. (1997) 62(4):377-383.
   PubMed Web of Science ®Google Scholar
• BLAKE MJ, GAEDIGK A, PEARCE RE et al.: Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. (2007) 81(4):510-516.
   PubMed Web of Science ®Google Scholar
• MARSHALL JD, KEARNS GL: Developmental pharmacodynamics of cyclosporine. Clin. Pharmacol. Ther. (1999) 66(1):66-75.
   PubMed Web of Science ®Google Scholar
• JACQZ-AIGRAIN E, DAOUD P, BURTIN P, DESPLANQUES L, BEAUFILS F: Placebo-controlled trial of midazolam sedation in mechanically ventilated newborn babies. Lancet (1994) 344(8923):646-650.
   PubMed Web of Science ®Google Scholar
• DE WILDT SN, DE HOOG M, VINKS AA, JOOSTEN KF, VAN DIJK M, VAN DEN ANKER JN: Pharmacodynamics of midazolam in pediatric intensive care patients. Ther. Drug Monit. (2005) 27(1):98-102.
   PubMed Web of Science ®Google Scholar
• RELLING MV, YANG W, DAS S et al.: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J. Clin. Oncol. (2004) 22(19):3930-3936.
   PubMed Web of Science ®Google Scholar
• SCHEFFNER D, KONIG S: Valproate hepatotoxicity. Lancet (1987) 1(8529):389-390.
   PubMedGoogle Scholar
• SANDERSON S, EMERY J, HIGGINS J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. (2005) 7(2):97-104.
   PubMed Web of Science ®Google Scholar
• ALBERS LJ, OZDEMIR V: Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr. Med. Chem. (2004) 11(3):297-312.
   PubMed Web of Science ®Google Scholar
• BURCZYNSKI ME, OESTREICHER JL, CAHILLY MJ et al.: Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr. Mol. Med. (2005) 5(1):83-102.
   PubMed Web of Science ®Google Scholar
• OZDEMIR V, SHEAR NH, KALOW W: What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf. (2001) 24(2):75-85.
   PubMed Web of Science ®Google Scholar
• TREPICCHIO WL, WILLIAMS GA, ESSAYAN D et al.: Pharmacogenomic data submissions to the FDA: clinical case studies. Pharmacogenomics (2004) 5(5):519-524.
   PubMed Web of Science ®Google Scholar
• GANIERE-MONTEIL C, MEDARD Y, LEJUS C et al.: Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. (2004) 60(2):89-96.
   PubMed Web of Science ®Google Scholar
• BEAL S, BOECKMANN A, SHEINER L: NONMEM User's Guide. San Fransisco: University of California at San Fransisco (1999).
   Google Scholar
• LUNN DJ, BEST N, THOMAS A, WAKEFIELD J, SPIEGELHALTER D: Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokinet. Pharmacodyn. (2002) 29(3):271-307.
   PubMed Web of Science ®Google Scholar
• BERRY DA: Bayesian clinical trials. Nat. Rev. Drug Discov. (2006) 5(1):27-36.
   PubMed Web of Science ®Google Scholar
• BRADFORD LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics (2002) 3(2):229-243.
   PubMed Web of Science ®Google Scholar
• MIZUTANI T: PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. (2003) 35(2-3):99-106.
   PubMed Web of Science ®Google Scholar
• XIE HG, PRASAD HC, KIM RB, STEIN CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. (2002) 54(10):1257-1270.
   PubMed Web of Science ®Google Scholar
• KIRCHHEINER J, NICKCHEN K, BAUER M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry (2004) 9(5):442-473.
   PubMed Web of Science ®Google Scholar
• RAKHMANINA NY, VAN DEN ANKER JN: Pharmacological research in pediatrics: from neonates to adolescents. Adv. Drug Deliv. Rev. (2006) 58(1):4-14.
   PubMed Web of Science ®Google Scholar
• WEINSHILBOUM R: Inheritance and drug response. N. Engl. J. Med. (2003) 348(6):529-537.
   PubMed Web of Science ®Google Scholar
• EVANS WE, MCLEOD HL: Pharmacogenomics–drug disposition, drug targets, and side effects. N. Engl. J. Med. (2003) 348(6):538-549.
   PubMed Web of Science ®Google Scholar
• LEEDER JS: Developmental and pediatric pharmacogenomics. Pharmacogenomics (2003) 4(3):331-341.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.emea.eu.int/pdfs/human/ich/43798606en.pdf Note for guidance on establishing definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories (2006).
   Google Scholar
• http://www.bnfc.org Website of the British National Formulary for Children (Accessed 2006).
   Google Scholar
• http://www.york.ac.uk/res/pgx/publications/eur22214wp3.pdf Regulatory and Quality Assurance Frameworks for PGx: a comparative study of the US, EU and four EU Member States (2006).
   Google Scholar
• http://www.emea.eu.int/pdfs/human/pharmacogenetics/12851706en.pdf Reflection paper on the use of pharmacogenetics in the pharmacokinetic evaluation of medicinal products (2006).
   Google Scholar
• http://www.emea.europa.eu/humandocs/Humans/EPAR/herceptin/herceptinM.htm European Public Assessment Report of Herceptin (Accessed December 2006).
   Google Scholar
• http://www.emea.europa.eu/humandocs/Humans/EPAR/glivec/glivecM.htm European Public Assessment Report of Glivec (Accessed December 2006).
   Google Scholar
• http://www.emea.europa.eu/humandocs/Humans/EPAR/erbitux/erbituxM.htm European Public Assessment Report of Erbitux (Accessed December 2006).
   Google Scholar
• www.fda.gov/medwatch/SAFETY/2005/Jun_PI/Camptosar_PI.pdf Final Label of Camptosar by the FDA (Accessed December 2006).
   Google Scholar
• www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=mercaptopurine Product Label of 6-mercaptopurine by the FDA (Accessed December 2006).
   Google Scholar